These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Efalizumab-associated thrombocytopenia. Hostetler SG; Zirwas M; Bechtel MA J Am Acad Dermatol; 2007 Oct; 57(4):707-10. PubMed ID: 17637485 [TBL] [Abstract][Full Text] [Related]
6. Thrombocytopenia in a psoriatic patient sequentially treated with adalimumab, secukinumab and ustekinumab. Nakahara T; Konishi S; Yasukochi Y; Esaki H; Tsuji G; Kido-Nakahara M; Furue M J Dermatol; 2019 May; 46(5):e157-e158. PubMed ID: 30353917 [No Abstract] [Full Text] [Related]
7. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis. Teraki Y; Takahashi A; Inoue Y; Takamura S Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064 [No Abstract] [Full Text] [Related]
8. Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris. de Groot M; de Rie MA; Bos JD Br J Dermatol; 2005 Oct; 153(4):843-4. PubMed ID: 16181475 [No Abstract] [Full Text] [Related]
15. Recurrent angioedema associated with efalizumab. Mallbris L; von Bergen F; van Hage M; Ståhle M Acta Derm Venereol; 2009 Nov; 89(6):665-6. PubMed ID: 19997712 [No Abstract] [Full Text] [Related]
16. Efalizumab-associated papular psoriasis: an adverse reaction to efalizumab in three cases. Antonucci A; Bardazzi F; Balestri R; Patrizi A J Dermatolog Treat; 2009; 20(1):61-2. PubMed ID: 18618361 [TBL] [Abstract][Full Text] [Related]
17. [Final recommendations to incorporate efalizumab into the clinical practice]. García-Díez A; Ferrándiz C Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():82. PubMed ID: 18341857 [No Abstract] [Full Text] [Related]
18. De novo onset of arthritis in patients previously treated with efalizumab: an observational case series. Colina M; Cianco G; Khodeir M; Sferra S; Scanavacca P; Corazza M; Virgili A; Trotta F Clin Exp Rheumatol; 2011; 29(1):141. PubMed ID: 21345301 [No Abstract] [Full Text] [Related]
19. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM; Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570 [TBL] [Abstract][Full Text] [Related]
20. Psoriasis-associated aseptic pneumonitis: another cause of lung involvement in psoriasis. Suárez-Amor O; Monteagudo B; Cabanillas M; Ramírez-Santos A Australas J Dermatol; 2014 Nov; 55(4):306. PubMed ID: 25399794 [No Abstract] [Full Text] [Related] [Next] [New Search]